Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muraglitazar + Metformin vs Glimepiride + Metformin in T2DM
NCT00095030Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of muraglitazar in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Change in baseline HbA1c at 52 weeks. Started Feb 2004; status: completed.
02
Drugs
muraglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00095030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095030.